Pegylated recombinant human endostatin (Tsinghua University)

聚乙二醇重组人血管内皮抑制素（清华大学）

Report date: 2022/03/10 15:38:30

Base Information

Drug NamePegylated recombinant human endostatin (Tsinghua University)
Drug Alias NameM-2ESCRB-0401
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionAngiogenesis inhibitorsVascular endothelial growth factor receptor antagonistsIntegrin alpha-5/beta-1 antagonists +[4] 
TargetsNucleolinIntegrin alpha-5/beta-1Vascular endothelial growth factor receptor
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungPancreatic Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesTsinghua UniversityBeijing Protgen Biotechnology Development Co LtdBeijing Proji Pharmaceutical Technology Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesBeijing Protgen Biotechnology Development Co LtdTsinghua University
Inactive CompaniesProtgen LtdSun Yat-Sen University
Active IndicationsCarcinoma, Non-Small-Cell Lung
Inactive IndicationsSolid tumoursPancreatic NeoplasmsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A